Margolis D A, Cammita B M
Medical College of Wisconsin, Department of Pediatrics, Milwaukee 53226, USA.
Curr Opin Hematol. 1998 Nov;5(6):441-4. doi: 10.1097/00062752-199811000-00015.
Severe aplastic anemia (SAA) appears to be an immunologically mediated disorder that results in deficient and defective hematopoietic stem cells. Both immune suppression and hematopoietic stem cell transplantation provide effective treatment for SAA. Optimal choice between these therapies depends upon a complex interaction of patient age, disease severity, overall patient health, and donor availability. Recent publications provide additional information on the long-term efficacy and toxicity of both treatments. Prospective studies with long-term follow-up are needed to put these and newer treatments in proper perspective.
重型再生障碍性贫血（SAA）似乎是一种免疫介导的疾病，可导致造血干细胞数量不足和功能缺陷。免疫抑制和造血干细胞移植均为SAA提供了有效的治疗方法。这两种治疗方法的最佳选择取决于患者年龄、疾病严重程度、患者整体健康状况以及供体可用性等复杂因素的相互作用。近期的出版物提供了关于这两种治疗方法长期疗效和毒性的更多信息。需要进行长期随访的前瞻性研究，以便正确看待这些治疗方法和更新的治疗方法。
